DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes | Zendy

Thomas Blevins | Zendy; John Pullman | Zendy; Jaret Malloy | Zendy; Ping Yan | Zendy; Kristin Taylor | Zendy; Christine T. Schulteis | Zendy; Michael Trautmann | Zendy; Lisa A. Porter | Zendy

Open Access

DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes

Author(s) -

Thomas Blevins,

John Pullman,

Jaret Malloy,

Ping Yan,

Kristin Taylor,

Christine T. Schulteis,

Michael Trautmann,

Lisa A. Porter

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2010-2081

Subject(s) - exenatide , medicine , glycemic , type 2 diabetes , adverse effect , diabetes mellitus , population , dulaglutide , weight loss , nausea , endocrinology , hypoglycemia , gastroenterology , obesity , environmental health

We wanted to understand the effects of once-weekly vs. twice-daily glucagon-like peptide-1 receptor agonism for treatment of patients with type 2 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog